The supplied records describe two distinct biotechnology-company equity inducement events rather than one reconciled award. Seres Therapeutics reported options covering 4,200 common shares for two new employees, while Crescent Biopharma reported options covering 58,650 ordinary shares for two non-executive employees. The companies, plans, exercise prices and vesting schedules differ, so the records cannot be consolidated into a single award without disregarding material facts.